- Home
- IRON vs DFIN Comparison
IRON vs DFIN Comparison
Compare IRON & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- DFIN
- Stock Information
- Founded
- IRON 2017
- DFIN 1983
- Country
- IRON United States
- DFIN United States
- Employees
- IRON N/A
- DFIN N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- DFIN Other Consumer Services
- Sector
- IRON Health Care
- DFIN Consumer Discretionary
- Exchange
- IRON Nasdaq
- DFIN Nasdaq
- Market Cap
- IRON 1.4B
- DFIN 1.2B
- IPO Year
- IRON N/A
- DFIN N/A
- Fundamental
- Price
- IRON $51.61
- DFIN $59.76
- Analyst Decision
- IRON Strong Buy
- DFIN Strong Buy
- Analyst Count
- IRON 10
- DFIN 3
- Target Price
- IRON $93.40
- DFIN $68.67
- AVG Volume (30 Days)
- IRON 372.4K
- DFIN 222.2K
- Earning Date
- IRON 08-07-2025
- DFIN 07-30-2025
- Dividend Yield
- IRON N/A
- DFIN N/A
- EPS Growth
- IRON N/A
- DFIN N/A
- EPS
- IRON N/A
- DFIN 3.01
- Revenue
- IRON N/A
- DFIN $779,600,000.00
- Revenue This Year
- IRON N/A
- DFIN $1.99
- Revenue Next Year
- IRON N/A
- DFIN $4.64
- P/E Ratio
- IRON N/A
- DFIN $20.02
- Revenue Growth
- IRON N/A
- DFIN N/A
- 52 Week Low
- IRON $30.82
- DFIN $37.80
- 52 Week High
- IRON $68.73
- DFIN $71.01
- Technical
- Relative Strength Index (RSI)
- IRON 56.99
- DFIN 69.95
- Support Level
- IRON $48.87
- DFIN $56.29
- Resistance Level
- IRON $54.13
- DFIN $60.64
- Average True Range (ATR)
- IRON 2.31
- DFIN 1.13
- MACD
- IRON 0.07
- DFIN 0.13
- Stochastic Oscillator
- IRON 67.64
- DFIN 87.99
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.